- Medpace press release ( NASDAQ: MEDP ): Q4 GAAP EPS of $2.12 beats by $0.33 .
- Revenue of $394.1M (+27.7% Y/Y) beats by $8.01M .
- EBITDA was $80.4 million for the fourth quarter of 2022, an increase of 30.9% from EBITDA of $61.4 million for the comparable prior-year period, resulting in an EBITDA margin of 20.4%.
- Net new business awards were $485.1 million in the fourth quarter of 2022, representing an increase of 5.8% from net new business awards of $458.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x.
- The Company forecasts 2023 revenue in the range of $1.690 billion to $1.750 billion vs $1.70B Consensus representing growth of 15.8% to 19.9% over 2022 revenue of $1.460 billion.
- GAAP net income for full year 2023 is forecasted in the range of $245.0 million to $265.0 million. Additionally, full year 2023
- EBITDA is expected in the range of $325.0 million to $350.0 million.
- Based on forecasted 2023 revenue of $1.690 billion to $1.750 billion and GAAP net income of $245.0 million to $265.0 million, diluted earnings per share (GAAP) is forecasted in the range of $7.53 to $8.14.
For further details see:
Medpace GAAP EPS of $2.12 beats by $0.33, revenue of $394.1M beats by $8.01M